✦ LIBER ✦

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

✍ Scribed by Paul William Manley; Guido Bold; Josef Brüggen; Gabrielle Fendrich; Pascal Furet; Jürgen Mestan; Christian Schnell; Barbara Stolz; Thomas Meyer; Bernd Meyhack; Wilhelm Stark; Andre Strauss; Jeanette Wood

Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 503 KB
Volume: 1697
Category: Article
ISSN: 1570-9639
DOI: 10.1016/j.bbapap.2003.11.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the structural biology, desi

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

✍ Paul William Manley; Sandra W. Cowan-Jacob; Jürgen Mestan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 373 KB

ChemInform Abstract: Protein Kinase C in

ChemInform Abstract: Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development

✍ Peter G. Goekjian; Michael R. Jirousek 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 25 KB 👁 3 views

Development and validation of a high-per

Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study

✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti